The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
|Articles|April 2, 2015
- Pharmaceutical Technology-04-02-2015
- Volume 39
- Issue 4
Quattroflow Diaphragm Pump Ensures Product Containment
Quattroflow’s QF1200CV is a compact quaternary diaphragm pump designed for tabletop and cleanroom applications.
Quattroflow’s QF1200CV is a compact quaternary diaphragm pump designed for tabletop and cleanroom applications. The pump chamber, pump drive, motor, and control box are combined in one unit, increasing its compact design and efficiency.
The pumps feature flow ranges from 10-1200 L/hr (2.64-317 gph), with a single-phase 230V motor and multiple-use or single-use options. Single-use models are constructed using machined polypropylene or injection-molded polyethylene. The multiple-use model offers clean-in-place/steaming-in-place, while both the polypropylene single-use and multiple-use models offer autoclavability. Total product containment is achieved with a four-piston design with no mechanical shaft seal or wetted rotating parts.
Articles in this issue
over 11 years ago
Evaluating Package Integrityover 11 years ago
Designing Trouble-Free Freeze-Drying Processesover 11 years ago
Modernizing Scale-Upover 11 years ago
Meissner Biocontainer Increases Customizabilityover 11 years ago
Ross Discharge System Increases Efficiencyover 11 years ago
West Vial Seal Reduces Risk of Contaminationover 11 years ago
Industry Expert Q&A with David Barrettover 11 years ago
The Role of Regulatory Advice in Drug DevelopmentRelated to this article
Florin Muraru, Gourav Pandey, and Richard Jaenisch explain where human sign-off belongs as multi-agent AI and document-parsing models reach GxP.
In this episode of Ask the Expert, Siegfried Schmitt, PhD, vice president, Technical at Parexel, and Susan J. Schniepp, distinguished fellow at Nelson Labs, discuss how companies should approach post-approval changes to their CMC regulatory filings.
The EC has approved AstraZeneca's Trixeo Aerosphere as the first single-inhaler triple-combination therapy for asthma in the EU, based on phase e data showing improved lung function and fewer severe exacerbations in patients uncontrolled on standard ICS/LABA treatment.
In this episode of Pharma Fundamentals, Dr. Aleksandra Zuraw, senior veterinary pathologist at Charles River, provides an introduction to the use of digital pathology in drug development.
Swedish biotech companies have a broad and varied product pipeline that is attracting attention from venture capitalists and pharmaceutical companies.
The agency issued a direct final rule that supports the use of innovative testing methods to limit the use of animals and maintain existing safety standards.
Jaenisch, Muraru, and Pandey debate whether AI "slop" is infiltrating pharma SOPs and deviation reports and who should catch it first.
Trending on Pharmaceutical Technology
1
EU Clears AstraZeneca's Trixeo for Asthma, Opening New Manufacturing Demand for Single-Inhaler Triple Therapy
2
The FDA Finalizes Rule Recognizing Non-Animal Testing Methods, Building on Year-Long Reduction Push
3
Weekly Basal Insulin Efsitora: A New Biologics CMC Benchmark
4
PharmTech AI Pulse Check: Fixing AI Slop at the Source
5